Advanced Solid Tumors

Positive preliminary results announced for VEGF Trap study in solid tumors

Published in Cancer Weekly, July 6th, 2004

Regeneron Pharmaceuticals, Inc., (REGN) announced positive preliminary results from the phase I trial for the company's vascular endothelial growth factor (VEGF) Trap in patients with advanced solid tumors.

Jakob Dupont, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center, summarized clinical data from this phase I trial in an oral presentation at the annual meeting of the American Society of Clinical Oncology (ASCO).These results are part of a clinical development collaboration agreement with Aventis to jointly develop and commercialize the VEGF Trap with Regeneron. The joint development program includes both cancer and eye diseases and budgets...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-07-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry